December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Continuing Evaluation of Gene Therapy In The Rpe65 Mutant Dog
Author Affiliations & Notes
  • GM Acland
    James A Baker Institute Cornell University Ithaca NY
  • GD Aguirre
    James A Baker Institute Cornell University Ithaca NY
  • TS Aleman
    Scheie Eye Institute University of Pennsylvania Philadelphia PA
  • AV Cideciyan
    Scheie Eye Institute University of Pennsylvania Philadelphia PA
  • AM Maguire
    Scheie Eye Institute University of Pennsylvania Philadelphia PA
  • SG Jacobson
    Scheie Eye Institute University of Pennsylvania Philadelphia PA
  • WW Hauswirth
    University of Florida Gainesville FL
  • J Bennett
    Scheie Eye Institute University of Pennsylvania Philadelphia PA PA
  • Footnotes
    Commercial Relationships   G.M. Acland, None; G.D. Aguirre, None; T.S. Aleman, None; A.V. Cideciyan, None; A.M. Maguire, None; S.G. Jacobson, None; W.W. Hauswirth, None; J. Bennett, None. Grant Identification: Support: NIH/NEI EY06855, EY10820, EY11123, EY13132, EY13385, EY13729; Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4593. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      GM Acland, GD Aguirre, TS Aleman, AV Cideciyan, AM Maguire, SG Jacobson, WW Hauswirth, J Bennett; Continuing Evaluation of Gene Therapy In The Rpe65 Mutant Dog . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4593.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate the long term effects on visual function of intraocular delivery of rAAV-RPE65 to RPE65 mutant dogs, a naturally occurring model of human Leber congenital amaurosis. Methods: As part of our earlier study, three RPE65 mutant dogs were injected, subretinally in one eye and intravitreally in the contralateral eye, with a recombinant adeno-associated virus carrying a chicken beta-actin promoter-driven canine cDNA encoding wildtype RPE65 (rAAV-RPE65). Restoration of visual function was demonstrated in the subretinally injected eyes 3 months after the injection (Acland at al., 2001).Two of these dogs are now studied at 13 months post-treatment. Dark-adapted ERG b-wave intensity response series were obtained; ERG photoresponses were recorded and fitted with a phototransduction model to quantify photoreceptor function. Light-adapted 29 Hz flicker was used to isolate cone function. Visually guided behaviour was also evaluated clinically. Results:The remarkable improvement in ERG parameters observed in subretinally injected eyes at 3 months remained unchanged 10 months later. ERG b-wave thresholds in these eyes were 3-4 log units lower than untreated eyes. Photoresponse amplitudes were substantial and sensitivity was close to the normal range. Cone 30Hz flicker was clearly detected. In contrast, ERGs of intravitreally injected eyes remained similar to those of untreated RPE65 deficient eyes: ERG b-wave thresholds were markedly elevated; small photoresponses were only detectable at the highest intensity; and cone flicker was not detectable. Behavioral assessment supported the ERG findings. Conclusion: The restoration of visual function in the RPE65 mutant dog achieved by subretinal delivery of rAVV-RPE65 persists for at least 13 months post-treatment and the magnitude of this effect is unchanged.

Keywords: 562 retinal degenerations: hereditary • 419 gene transfer/gene therapy • 316 animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×